Purespring Raises $105 Million for Kidney Disease Research
Purespring Therapeutics, a pioneering gene therapy company based in London, UK, is focusing its efforts on revolutionizing the treatment landscape for kidney diseases. Recently, the company successfully raised an impressive $105 million in a Series B funding round, which was primarily led by Sofinnova Partners. This funding round also saw the collaboration of a robust syndicate comprising Gilde Healthcare, Forbion, British Patient Capital, and the founding investor, Syncona Limited. With these substantial financial resources, Purespring is poised to bolster its research and development pipelines significantly.
The newly acquired funds will primarily support the initiation of a Phase I/II clinical trial aimed at tackling IgA Nephropathy (IgAN), a prevalent and chronic kidney condition that predominantly impacts young adults.
The company’s strategy involves the innovative targeting of podocytes, a specialized type of cell that plays a critical role in approximately 60% of renal diseases. Under the leadership of CEO Julian Hanak, Purespring employs its proprietary adeno-associated viral (AAV) gene therapy platform to address kidney disease models, thereby promising a more effective treatment approach for this challenging condition. In addition to its leading IgAN program, Purespring is also working on other complement-mediated kidney diseases, nephrotic syndrome, and an undisclosed program focused on glomerular kidney diseases.
As part of its ongoing commitment to transparency and knowledge sharing in the scientific community, Purespring intends to present its IgAN data publicly for the first time at the American Society of Nephrology (ASN) Kidney Week congress. This event is scheduled to occur on October 26 in San Diego, where researchers and healthcare professionals will gather to discuss the latest advancements in kidney health and disease management. The abstract for this significant presentation is labeled #SA-OR63, indicating the importance Purespring places on its research findings and the potential implications for future therapy developments in the field of nephrology.
They've invested in Purespring Therapeutics
Get to know these Healthtech investors
| # | Investor | Sector | Stage | Activity | Team | Connect |
|---|---|---|---|---|---|---|
1 |  Sofinnova Partners | 9 investment(s) investment(s) | 29 contacts contacts | |||
2 |  Gilde Healthcare | 1 investment(s) investment(s) | more info | |||
3 |  Forbion | 10 investment(s) investment(s) | more info | |||
4 |  British Patient Capital | 10 investment(s) investment(s) | 25 contacts contacts | |||
5 |  Syncona Limited | investment(s) investment(s) | more info |
Click here for a full list of 6,528+ startup investors in the UK